Skip to content
OpenCapital
Get started

AYTU BioPharma, Inc. AYTU Q4 2025 earnings

Reported February 3, 2026 · After market close

Revenue$15.2MBeat by $3.0MDiluted EPS-$1.05Miss by $0.79
Revenue estimate$12.2M
EPS estimate-$0.26

Next report

Sep 22, 2026 (in 2 months)
Revenue estimate$17.2M
EPS estimate-$0.22

Versus estimates

Revenue

Q1 2026$12.4MBeat by $358.3K
Q4 2025$15.2MBeat by $3.0M
Q3 2025$13.9MBeat by $1.3MQ2 2025$15.1MMiss by $2.8MQ1 2025$18.5MMiss by $380.5KQ4 2024$16.2MMiss by $1.4M

Diluted EPS

Q1 2026-$0.53Miss by $0.22
Q4 2025-$1.05Miss by $0.79
Q3 2025-$0.08Miss by $0.02Q2 2025-$0.26Miss by $0.24Q1 2025$0.20Beat by $0.37Q4 2024-$0.28In line

Ask the moment AYTU BioPharma, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did AYTU BioPharma, Inc. report Q4 2025 earnings?
AYTU BioPharma, Inc. (AYTU) reported Q4 2025 earnings on February 3, 2026 after market close.
What were AYTU BioPharma, Inc.'s Q4 2025 revenue and EPS?
AYTU BioPharma, Inc. reported revenue of $15.2M and diluted EPS of $-1.05 for Q4 2025.
Did AYTU BioPharma, Inc. beat estimates in Q4 2025?
Revenue beat the consensus estimate of $12.2M by $3.0M. EPS missed the consensus estimate of $-0.26 by $0.79.
How did AYTU BioPharma, Inc.'s Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 6.3% from $16.2M a year earlier and diluted EPS declined 275.0% from $-0.28.
Where can I find AYTU BioPharma, Inc.'s Q4 2025 SEC filings?
You can read the 8-K earnings release (0001437749-26-002799) and the 10-Q periodic report (0001437749-26-002804) directly on SEC EDGAR. The filing index links above go to sec.gov.